NURS 6521 ADVANCED PHARMACOLOGY COMPREHENSIVE MIDTERM EXAM
PRACTICE 2026/2027: 150+ VERIFIED QUESTIONS WITH RATIONALES, FULL
TESTBANK, AND ADVANCED REVIEW FOR GRADUATE NURSING CERTIFICATION
i. Pharmacokinetics and Pharmacodynamics
i. Absorption, Distribution, Metabolism, Excretion
ii. First-Pass Effect, Bioavailability, Volume of Distribution
iii. Half-Life, Steady State, Therapeutic Index
iv. Receptor Theory, Agonists, Antagonists, Partial Agonists
ii. Pharmacogenomics and Individualized Medicine
i. CYP450 Polymorphisms (CYP2D6, CYP2C19, CYP2C9)
ii. HLA-B5701, DPYD, VKORC1, TPMT*
iii. Genetic Testing and Clinical Decision-Making
iii. Autonomic and Central Nervous System Pharmacology
i. Sympathomimetics, Sympatholytics, Parasympatholytics
ii. Anticonvulsants, Antipsychotics, Antidepressants, Anxiolytics
iii. Opioid and Non-Opioid Analgesics, Migraine Therapies
iv. Cardiovascular and Renal Pharmacology
i. Antihypertensives, Antiarrhythmics, Heart Failure Agents
ii. Anticoagulants, Antiplatelets, Thrombolytics
iii. Diuretics, Electrolyte Management, Renal Dosing
v. Antimicrobial and Anti-Infective Therapy
i. Antibacterials, Antivirals, Antifungals, Antimycobacterials
ii. Antimicrobial Stewardship, Resistance, Prophylaxis
iii. Immunizations and Biologic Response Modifiers
vi. Endocrine and Reproductive Pharmacology
i. Diabetes Agents, Thyroid Agents, Corticosteroids
ii. Hormonal Contraceptives, HRT, Bone Health
iii. Men's and Women's Health Pharmacotherapy
vii. Geriatric, Pediatric, and Special Populations
i. Age-Related Pharmacokinetic Changes
ii. Beers Criteria, Deprescribing, Polypharmacy
iii. Pregnancy, Lactation, Pediatric Dosing
viii. Professional, Legal, and Ethical Prescribing
i. Prescriptive Authority, DEA Regulations, Controlled Substances
,ii. Documentation, Monitoring, Patient Education
iii. Adverse Drug Events, Drug Interactions, Pharmacovigilance
DESCRIPTION
This comprehensive practice examination for NURS 6521 Advanced Pharmacology
is designed for Master of Science in Nursing students, Nurse Practitioner
candidates, and advanced practice registered nurses preparing for midterm and
certification assessments. The exam covers pharmacokinetics, pharmacodynamics,
pharmacogenomics, major drug classifications, prescribing regulations, and clinical
decision-making across the lifespan. Questions are scenario-based and require
critical thinking, analysis, and application of pharmacological principles. Each
question includes a verified correct answer and a concise rationale to reinforce
learning. This resource contains 150 practice questions and answers with
rationales. Purchase and instantly get a downloadable and editable PDF.
Question 1
A 68-year-old patient with decompensated heart failure and hepatic congestion is
prescribed a highly protein-bound drug. Which pharmacokinetic alteration should
the nurse practitioner anticipate?
A. Decreased volume of distribution due to increased free drug fraction
B. Increased volume of distribution due to fluid retention
C. Decreased free drug concentration due to enhanced protein binding
D. No change in pharmacokinetics with hepatic congestion
🔴 Correct Answer: A. Decreased volume of distribution due to increased free
drug fraction
🔵 Explanation: Hepatic congestion reduces albumin synthesis, decreasing protein
binding and increasing free drug fraction. This reduces the apparent volume of
distribution for highly protein-bound drugs and increases risk of toxicity from free
drug.
Question 2
A patient with a CYP2C19 poor metabolizer phenotype is started on clopidogrel
following stent placement. The nurse practitioner anticipates which clinical
outcome?
A. Enhanced antiplatelet effect requiring dose reduction
B. Reduced activation of clopidogrel and increased risk of stent thrombosis
C. Increased risk of gastrointestinal bleeding
D. No difference in clinical outcomes compared to normal metabolizers
🔴 Correct Answer: B. Reduced activation of clopidogrel and increased risk of
stent thrombosis
,🔵 Explanation: CYP2C19 converts clopidogrel to its active metabolite. Poor
metabolizers have reduced conversion and diminished antiplatelet effect, increasing
thrombosis risk. Alternative antiplatelet therapy should be considered.
Question 3
A 72-year-old patient with atrial fibrillation is prescribed amiodarone. Which
baseline and periodic monitoring parameters are essential?
A. CBC and renal function only
B. Liver function, thyroid function, pulmonary function, and chest x-ray
C. Serum electrolytes and urine output only
D. Echocardiogram and exercise stress test only
🔴 Correct Answer: B. Liver function, thyroid function, pulmonary function, and
chest x-ray
🔵 Explanation: Amiodarone can cause hepatotoxicity, thyroid dysfunction (hypo- or
hyperthyroidism), and pulmonary toxicity. Baseline and periodic monitoring of these
parameters is essential for safe therapy.
Question 4
A patient receiving vancomycin develops increased serum creatinine and
decreased urine output. Which action should the nurse practitioner take first?
A. Continue vancomycin and recheck creatinine in 48 hours
B. Hold vancomycin and obtain a serum vancomycin trough level
C. Double the vancomycin dose to ensure efficacy
D. Switch to oral vancomycin for systemic effect
🔴 Correct Answer: B. Hold vancomycin and obtain a serum vancomycin trough
level
🔵 Explanation: Vancomycin is nephrotoxic. Rising creatinine and oliguria indicate
possible acute kidney injury. The drug should be held, and trough levels should guide
dosing or discontinuation.
Question 5
A patient with a known DPYD gene variant is prescribed fluorouracil (5-FU). What
is the appropriate action?
A. Use standard dosing with close monitoring
B. Significantly reduce dose or avoid due to risk of severe toxicity
C. Double the dose to overcome resistance
D. Add leucovorin to counteract toxicity
🔴 Correct Answer: B. Significantly reduce dose or avoid due to risk of severe
toxicity
🔵 Explanation: DPYD deficiency impairs 5-FU catabolism, leading to life-
, threatening myelosuppression and mucositis. Dose reduction or alternative therapy
is required.
Question 6
Which drug requires HLA-B*5701 screening before initiation to prevent
hypersensitivity syndrome?
A. Efavirenz
B. Abacavir
C. Tenofovir
D. Raltegravir
🔴 Correct Answer: B. Abacavir
🔵 Explanation: HLA-B5701 screening is mandatory before abacavir use. Positive
patients have a near-100% risk of abacavir hypersensitivity syndrome, which can
be fatal.*
Question 7
A 55-year-old patient with hypertension and diabetes is prescribed lisinopril.
Which laboratory tests should be monitored periodically?
A. CBC and liver function
B. Potassium and creatinine
C. INR and thyroid function
D. Calcium and phosphate
🔴 Correct Answer: B. Potassium and creatinine
🔵 Explanation: ACE inhibitors can cause hyperkalemia and increase creatinine by
reducing angiotensin II-mediated renal perfusion. Periodic monitoring is essential.
Question 8
A patient on warfarin has a supratherapeutic INR of 6.2 without bleeding. Which
intervention is most appropriate?
A. Administer vitamin K 10 mg IV
B. Hold warfarin and monitor INR
C. Administer fresh frozen plasma
D. Continue warfarin and recheck in 72 hours
🔴 Correct Answer: B. Hold warfarin and monitor INR
🔵 Explanation: For INR 5–9 without bleeding, warfarin should be held and INR
monitored. Vitamin K is reserved for serious bleeding or very high INR with bleeding
risk.
Question 9
Which antibiotic is most appropriate for a patient with penicillin allergy and
PRACTICE 2026/2027: 150+ VERIFIED QUESTIONS WITH RATIONALES, FULL
TESTBANK, AND ADVANCED REVIEW FOR GRADUATE NURSING CERTIFICATION
i. Pharmacokinetics and Pharmacodynamics
i. Absorption, Distribution, Metabolism, Excretion
ii. First-Pass Effect, Bioavailability, Volume of Distribution
iii. Half-Life, Steady State, Therapeutic Index
iv. Receptor Theory, Agonists, Antagonists, Partial Agonists
ii. Pharmacogenomics and Individualized Medicine
i. CYP450 Polymorphisms (CYP2D6, CYP2C19, CYP2C9)
ii. HLA-B5701, DPYD, VKORC1, TPMT*
iii. Genetic Testing and Clinical Decision-Making
iii. Autonomic and Central Nervous System Pharmacology
i. Sympathomimetics, Sympatholytics, Parasympatholytics
ii. Anticonvulsants, Antipsychotics, Antidepressants, Anxiolytics
iii. Opioid and Non-Opioid Analgesics, Migraine Therapies
iv. Cardiovascular and Renal Pharmacology
i. Antihypertensives, Antiarrhythmics, Heart Failure Agents
ii. Anticoagulants, Antiplatelets, Thrombolytics
iii. Diuretics, Electrolyte Management, Renal Dosing
v. Antimicrobial and Anti-Infective Therapy
i. Antibacterials, Antivirals, Antifungals, Antimycobacterials
ii. Antimicrobial Stewardship, Resistance, Prophylaxis
iii. Immunizations and Biologic Response Modifiers
vi. Endocrine and Reproductive Pharmacology
i. Diabetes Agents, Thyroid Agents, Corticosteroids
ii. Hormonal Contraceptives, HRT, Bone Health
iii. Men's and Women's Health Pharmacotherapy
vii. Geriatric, Pediatric, and Special Populations
i. Age-Related Pharmacokinetic Changes
ii. Beers Criteria, Deprescribing, Polypharmacy
iii. Pregnancy, Lactation, Pediatric Dosing
viii. Professional, Legal, and Ethical Prescribing
i. Prescriptive Authority, DEA Regulations, Controlled Substances
,ii. Documentation, Monitoring, Patient Education
iii. Adverse Drug Events, Drug Interactions, Pharmacovigilance
DESCRIPTION
This comprehensive practice examination for NURS 6521 Advanced Pharmacology
is designed for Master of Science in Nursing students, Nurse Practitioner
candidates, and advanced practice registered nurses preparing for midterm and
certification assessments. The exam covers pharmacokinetics, pharmacodynamics,
pharmacogenomics, major drug classifications, prescribing regulations, and clinical
decision-making across the lifespan. Questions are scenario-based and require
critical thinking, analysis, and application of pharmacological principles. Each
question includes a verified correct answer and a concise rationale to reinforce
learning. This resource contains 150 practice questions and answers with
rationales. Purchase and instantly get a downloadable and editable PDF.
Question 1
A 68-year-old patient with decompensated heart failure and hepatic congestion is
prescribed a highly protein-bound drug. Which pharmacokinetic alteration should
the nurse practitioner anticipate?
A. Decreased volume of distribution due to increased free drug fraction
B. Increased volume of distribution due to fluid retention
C. Decreased free drug concentration due to enhanced protein binding
D. No change in pharmacokinetics with hepatic congestion
🔴 Correct Answer: A. Decreased volume of distribution due to increased free
drug fraction
🔵 Explanation: Hepatic congestion reduces albumin synthesis, decreasing protein
binding and increasing free drug fraction. This reduces the apparent volume of
distribution for highly protein-bound drugs and increases risk of toxicity from free
drug.
Question 2
A patient with a CYP2C19 poor metabolizer phenotype is started on clopidogrel
following stent placement. The nurse practitioner anticipates which clinical
outcome?
A. Enhanced antiplatelet effect requiring dose reduction
B. Reduced activation of clopidogrel and increased risk of stent thrombosis
C. Increased risk of gastrointestinal bleeding
D. No difference in clinical outcomes compared to normal metabolizers
🔴 Correct Answer: B. Reduced activation of clopidogrel and increased risk of
stent thrombosis
,🔵 Explanation: CYP2C19 converts clopidogrel to its active metabolite. Poor
metabolizers have reduced conversion and diminished antiplatelet effect, increasing
thrombosis risk. Alternative antiplatelet therapy should be considered.
Question 3
A 72-year-old patient with atrial fibrillation is prescribed amiodarone. Which
baseline and periodic monitoring parameters are essential?
A. CBC and renal function only
B. Liver function, thyroid function, pulmonary function, and chest x-ray
C. Serum electrolytes and urine output only
D. Echocardiogram and exercise stress test only
🔴 Correct Answer: B. Liver function, thyroid function, pulmonary function, and
chest x-ray
🔵 Explanation: Amiodarone can cause hepatotoxicity, thyroid dysfunction (hypo- or
hyperthyroidism), and pulmonary toxicity. Baseline and periodic monitoring of these
parameters is essential for safe therapy.
Question 4
A patient receiving vancomycin develops increased serum creatinine and
decreased urine output. Which action should the nurse practitioner take first?
A. Continue vancomycin and recheck creatinine in 48 hours
B. Hold vancomycin and obtain a serum vancomycin trough level
C. Double the vancomycin dose to ensure efficacy
D. Switch to oral vancomycin for systemic effect
🔴 Correct Answer: B. Hold vancomycin and obtain a serum vancomycin trough
level
🔵 Explanation: Vancomycin is nephrotoxic. Rising creatinine and oliguria indicate
possible acute kidney injury. The drug should be held, and trough levels should guide
dosing or discontinuation.
Question 5
A patient with a known DPYD gene variant is prescribed fluorouracil (5-FU). What
is the appropriate action?
A. Use standard dosing with close monitoring
B. Significantly reduce dose or avoid due to risk of severe toxicity
C. Double the dose to overcome resistance
D. Add leucovorin to counteract toxicity
🔴 Correct Answer: B. Significantly reduce dose or avoid due to risk of severe
toxicity
🔵 Explanation: DPYD deficiency impairs 5-FU catabolism, leading to life-
, threatening myelosuppression and mucositis. Dose reduction or alternative therapy
is required.
Question 6
Which drug requires HLA-B*5701 screening before initiation to prevent
hypersensitivity syndrome?
A. Efavirenz
B. Abacavir
C. Tenofovir
D. Raltegravir
🔴 Correct Answer: B. Abacavir
🔵 Explanation: HLA-B5701 screening is mandatory before abacavir use. Positive
patients have a near-100% risk of abacavir hypersensitivity syndrome, which can
be fatal.*
Question 7
A 55-year-old patient with hypertension and diabetes is prescribed lisinopril.
Which laboratory tests should be monitored periodically?
A. CBC and liver function
B. Potassium and creatinine
C. INR and thyroid function
D. Calcium and phosphate
🔴 Correct Answer: B. Potassium and creatinine
🔵 Explanation: ACE inhibitors can cause hyperkalemia and increase creatinine by
reducing angiotensin II-mediated renal perfusion. Periodic monitoring is essential.
Question 8
A patient on warfarin has a supratherapeutic INR of 6.2 without bleeding. Which
intervention is most appropriate?
A. Administer vitamin K 10 mg IV
B. Hold warfarin and monitor INR
C. Administer fresh frozen plasma
D. Continue warfarin and recheck in 72 hours
🔴 Correct Answer: B. Hold warfarin and monitor INR
🔵 Explanation: For INR 5–9 without bleeding, warfarin should be held and INR
monitored. Vitamin K is reserved for serious bleeding or very high INR with bleeding
risk.
Question 9
Which antibiotic is most appropriate for a patient with penicillin allergy and
